GlassScriptPhysician profile
Shannon Drachenberg
NPI 1790093805
$3,862.23
in general payments reported to CMS, 2019-2025
26 companies · $904 in 2025
The $904 reported for 2025 was more than what 78% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $485 · 2022: $863 · 2023: $873 · 2024: $737 · 2025: $904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,501 · Education: $13.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,501.30 |
| Education | $13.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $998.94 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $530.73 | 2022-2025 | Airsupra, Saphnelo, Farxiga |
| Novo Nordisk INC | $477.61 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $409.34 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $252.90 | 2022-2025 | Trelegy Ellipta, Shingrix |
| Pfizer INC. | $136.45 | 2022-2025 | |
| Biohaven Pharmaceuticals, INC. | $127.91 | 2021 | |
| Amgen INC. | $119.27 | 2021-2025 | Otezla, Repatha, Repatha |
| Axonics, INC. | $116.50 | 2023 | Axonics |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.01 | 2021-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $108.63 | 2021-2025 | Trintellix |
| Dexcom, INC. | $106.25 | 2024-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $76.75 | 2021-2025 | |
| Gilead Sciences, INC. | $39.35 | 2021 | |
| Cmp Pharma, INC. | $30.51 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $29.60 | 2023 | Cologuard Collection Kit |
| Ardelyx, INC. | $28.68 | 2024 | Ibsrela |
| Amneal Pharmaceuticals LLC | $28.15 | 2022 | |
| Inspire Medical Systems, INC. | $22.42 | 2023 | Inspire |
| Abbott Laboratories | $21.11 | 2023 | Freestyle Libre 2 |
| Otsuka America Pharmaceutical, INC. | $18.44 | 2023 | Nuedexta |
| Xeris Pharmaceuticals, INC. | $17.44 | 2022 | |
| Esperion Therapeutics, INC. | $14.39 | 2021 | |
| Insulet Corporation | $14.16 | 2021 | |
| Genentech USA, INC. | $13.95 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Drachenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.